Bruker (NASDAQ:BRKR) had its price target trimmed by Morgan Stanley from $32.00 to $31.00 in a research note issued to investors on Wednesday. The brokerage currently has an equal weight rating on the medical research company’s stock.
Several other equities research analysts also recently issued reports on the company. Zacks Investment Research downgraded Bruker from a strong-buy rating to a hold rating in a report on Wednesday, January 3rd. Cowen reiterated a hold rating and set a $35.00 price target on shares of Bruker in a report on Thursday, December 21st. BidaskClub downgraded Bruker from a buy rating to a hold rating in a report on Saturday, February 10th. Evercore ISI initiated coverage on Bruker in a report on Wednesday, January 3rd. They set an in-line rating and a $36.00 price target for the company. Finally, BTIG Research initiated coverage on Bruker in a report on Friday, January 5th. They set a buy rating and a $42.00 price target for the company. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating and four have assigned a buy rating to the company’s stock. Bruker currently has a consensus rating of Hold and a consensus target price of $32.54.
Shares of Bruker stock opened at $30.17 on Wednesday. Bruker has a 12-month low of $21.83 and a 12-month high of $36.53. The firm has a market cap of $4,673.96, a P/E ratio of 24.56, a P/E/G ratio of 1.99 and a beta of 1.12. The company has a quick ratio of 1.66, a current ratio of 2.59 and a debt-to-equity ratio of 0.57.
The firm also recently disclosed a quarterly dividend, which was paid on Friday, March 23rd. Shareholders of record on Tuesday, March 6th were paid a $0.04 dividend. The ex-dividend date of this dividend was Monday, March 5th. This represents a $0.16 dividend on an annualized basis and a yield of 0.53%. Bruker’s dividend payout ratio (DPR) is presently 13.22%.
Large investors have recently made changes to their positions in the business. Bank of Montreal Can grew its stake in Bruker by 346.7% in the 4th quarter. Bank of Montreal Can now owns 3,708 shares of the medical research company’s stock valued at $128,000 after purchasing an additional 2,878 shares during the period. Zions Bancorporation purchased a new position in shares of Bruker during the 3rd quarter valued at $119,000. SG Americas Securities LLC purchased a new position in shares of Bruker during the 4th quarter valued at $145,000. The Manufacturers Life Insurance Company lifted its position in shares of Bruker by 7.1% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 5,003 shares of the medical research company’s stock valued at $144,000 after buying an additional 331 shares during the last quarter. Finally, Wolverine Trading LLC purchased a new position in shares of Bruker during the 4th quarter valued at $201,000. Hedge funds and other institutional investors own 65.27% of the company’s stock.
Bruker Company Profile
Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions worldwide. The company operates through two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry systems; infrared spectroscopy and radiological/nuclear detectors for chemical, biological, radiological, nuclear and explosive detection in emergency response, homeland security, and defense applications; and analytical and process analysis instruments and solutions.
Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.